Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Standardizing DLBCL Treatment: Dr. John Burke in a Riveting Conversation with PharmaShots  

Shots:   In the five-year follow-up data from the randomized POLARIX study, where participants received R-CHOP with a placebo for polatuzumab (control arm) and Pola-R-CHP with a placebo for vincristine   The primary endpoint of the study was progression free survival, and the secondary endpoint was overall survival  PharmaShots welcomes Dr. John Burke from Rocky Mountain Cancer…
3 days ago

Read more

VIEWPOINTS_Samantha Kerr_2023
VIEWPOINTS

Samantha Kerr shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)

Shots: Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+) Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…
October 5, 2023

Read more

VIEWPOINTS_Simon Portsmouth_2023
VIEWPOINTS

Simon Portsmouth Shares Insights from P-III Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Shots: Simon spoke about the enrollment of the first participant in Japan in the P-III (SCORPIO-PEP) study to evaluate the safety and efficacy of Ensitrelvir for the prevention of symptomatic SARS-CoV-2 infection He mentioned how this study will supplement data from the pivotal SCORPIO-SR trial's P-III segment which showed ensitrelvir's effectiveness in treating mild-to-moderate COVID-19…
September 18, 2023

Read more

VIEWPOINTS_Curtis Rambaran_2023
VIEWPOINTS

Curtis Rambaran’s Insights from Zerlasiran P-II Study for Patients with Elevated Lipoprotein (a) at High-Risk ASCVD Events

Shots: Curtis gave a brief introduction about Zerlasiran. He also talked about the study design and the results from the P-II trial (ALPACAR-360) under which Zerlasiran is being evaluated He also highlighted how Zerlasiran can differ from other therapies that are in development to treat elevated lipoprotein (a) at high risk of atherosclerotic cardiovascular disease (ASCVD)…
August 28, 2023

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]